api 20 c aux (bioMerieux gmbh)
90
Structured Review
bioMerieux gmbh
api 20 c aux
Api 20 C Aux, supplied by bioMerieux gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/api+20+c+aux/api+20c+aux/pm39612138-45-34-35
Average 90 stars, based on 1 article reviews
Api 20 C Aux, supplied by bioMerieux gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/api+20+c+aux/api+20c+aux/pm39612138-45-34-35
Average 90 stars, based on 1 article reviews
api 20 c aux - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Incubation:Article Title: Production of Herbal Vinegar Using Isolated Microorganisms from Traditional Herbal Vinegar Fermentation Article Snippet: The ability of five Article Title: Table Olives Fermented in Iodized Sea Salt Brines: Nutraceutical/Sensory Properties and Microbial Biodiversity Article Snippet: Biochemical identification was carried out by API 20 C Article Title: Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2018. Article Snippet: We surveyed Canadian Nosocomial Infection Surveillance Program hospitals to evaluate infection prevention and microbiology laboratory preparedness for Candida auris.. We identified significant gaps: most hospitals were not prepared to screen patients for colonization, and only one-half of laboratories reported identifying all clinically significant Candida isolates to the species level. (Received 2 October 2019; accepted 6 December 2019) Candida auris is a rapidly emerging, multidrug-resistant fungus that has caused outbreaks of severe infection in several countries.1–4 Difficulties in laboratory identification and lack of information about how best to identify colonized patients and prevent transmission make response to this emerging pathogen challenging.1,2,5 In Canada, the first multidrug-resistantC. auriswas reported in 2017.6 As of October 2019, 5 provinces had reported 24 cases with variable susceptibility (unpublished information, Public Health Agency of Canada).7 To date, no program has been implemented for systematic surveillance of C. auris in Canada, and data to inform best practices in microbiology and infection prevention and control (IPAC) remain sparse.. The Canadian Nosocomial Infection Surveillance Program (CNISP), a collaboration between the Public Health Agency of Canada and the Association of Medical Microbiology and Infectious Diseases Canada, formed a C. auris interest group in January 2018. Article Title: Investigation of clonal relationship in hospital-associated Candida parapsilosis isolates. Article Snippet: parapsilosis is also isolated from blood, skin, nails (hands of healthcare workers), medical plastics and surfaces of prosthetics [2–5].. C. parapsilosis complex includes three species: C. parapsilosis sensu stricto, C. orthopsilosis and C. metapsilosis [1, 5–8].. C. parapsilosis complex has emerged as one of the most important causes of disease, especially in immunocompromised patients and inpatients with underlying disease associated with parenteral nutrition and intravascular catheters [1, 9, 10]. Article Title: Evaluation of Rhodotorula spp. contamination in hospital environments. Article Snippet: Hospital air quality plays a key role in the transmission of nosocomial pathogens: numerous studies have shown that about 10% of infections acquired by hospital patients are of nosocomial origin (Gehanno et al., 2009).. Despite the adoption of strict sanitisation protocols by hospital facilities, the emergence of new opportunists, often of environmental origin, and the consequent development of resistant strains, cannot be avoided (Groll & Walsh, 2001; Miceli et al., 2011).. The prevention of the onset of nosocomial infections, given the increase in morbidity and mortality associated with them, is a priority for the maintenance of public health (Kowalski, 2016). Article Title: Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies. Article Snippet: Posaconazole (PSC) is a triazole group anti-fungal agent with the widest spectrum.. Although there is no commercially available ocular dosage form, its diluted oral suspension preparation (Noxafil®) is used as off-label in topical treatment of severe keratitis and sclerokeratitis in the clinic.. However, ocular bioavailability of PSC suspension form is extremely low due to its highly lipophilic character. Article Title: Oral mycobiome identification in atopic dermatitis, leukemia, and HIV patients – a systematic review Article Snippet: Only Mane et al. [ ] that studied HIV-infected patients made use of fermentation and assimilation tests using API 20 C Isolation:Article Title: Production of Herbal Vinegar Using Isolated Microorganisms from Traditional Herbal Vinegar Fermentation Article Snippet: The ability of five Article Title: Table Olives Fermented in Iodized Sea Salt Brines: Nutraceutical/Sensory Properties and Microbial Biodiversity Article Snippet: Biochemical identification was carried out by API 20 C Article Title: Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2018. Article Snippet: We surveyed Canadian Nosocomial Infection Surveillance Program hospitals to evaluate infection prevention and microbiology laboratory preparedness for Candida auris.. We identified significant gaps: most hospitals were not prepared to screen patients for colonization, and only one-half of laboratories reported identifying all clinically significant Candida isolates to the species level. (Received 2 October 2019; accepted 6 December 2019) Candida auris is a rapidly emerging, multidrug-resistant fungus that has caused outbreaks of severe infection in several countries.1–4 Difficulties in laboratory identification and lack of information about how best to identify colonized patients and prevent transmission make response to this emerging pathogen challenging.1,2,5 In Canada, the first multidrug-resistantC. auriswas reported in 2017.6 As of October 2019, 5 provinces had reported 24 cases with variable susceptibility (unpublished information, Public Health Agency of Canada).7 To date, no program has been implemented for systematic surveillance of C. auris in Canada, and data to inform best practices in microbiology and infection prevention and control (IPAC) remain sparse.. The Canadian Nosocomial Infection Surveillance Program (CNISP), a collaboration between the Public Health Agency of Canada and the Association of Medical Microbiology and Infectious Diseases Canada, formed a C. auris interest group in January 2018. Article Title: Investigation of clonal relationship in hospital-associated Candida parapsilosis isolates. Article Snippet: parapsilosis is also isolated from blood, skin, nails (hands of healthcare workers), medical plastics and surfaces of prosthetics [2–5].. C. parapsilosis complex includes three species: C. parapsilosis sensu stricto, C. orthopsilosis and C. metapsilosis [1, 5–8].. C. parapsilosis complex has emerged as one of the most important causes of disease, especially in immunocompromised patients and inpatients with underlying disease associated with parenteral nutrition and intravascular catheters [1, 9, 10]. Article Title: Evaluation of Rhodotorula spp. contamination in hospital environments. Article Snippet: Hospital air quality plays a key role in the transmission of nosocomial pathogens: numerous studies have shown that about 10% of infections acquired by hospital patients are of nosocomial origin (Gehanno et al., 2009).. Despite the adoption of strict sanitisation protocols by hospital facilities, the emergence of new opportunists, often of environmental origin, and the consequent development of resistant strains, cannot be avoided (Groll & Walsh, 2001; Miceli et al., 2011).. The prevention of the onset of nosocomial infections, given the increase in morbidity and mortality associated with them, is a priority for the maintenance of public health (Kowalski, 2016). Article Title: Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies. Article Snippet: Posaconazole (PSC) is a triazole group anti-fungal agent with the widest spectrum.. Although there is no commercially available ocular dosage form, its diluted oral suspension preparation (Noxafil®) is used as off-label in topical treatment of severe keratitis and sclerokeratitis in the clinic.. However, ocular bioavailability of PSC suspension form is extremely low due to its highly lipophilic character. Article Title: Oral mycobiome identification in atopic dermatitis, leukemia, and HIV patients – a systematic review Article Snippet: Only Mane et al. [ ] that studied HIV-infected patients made use of fermentation and assimilation tests using API 20 C |
